Fentanyl Citrate Preservative Free FDA Approved Drugs
ABSTRAL [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.1mg base (sublingual tablet)
eq 0.2mg base (sublingual tablet)
eq 0.3mg base (sublingual tablet)
eq 0.4mg base (sublingual tablet)
eq 0.6mg base (sublingual tablet)
eq 0.8mg base (sublingual tablet)
Sentynl Theraps IncJan 7, 2011
- Management of breakthrough pain in patients with cancer.
ACTIQ [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.2mg base (transmucosal troche/lozenge)
eq 0.4mg base (transmucosal troche/lozenge)
eq 0.6mg base (transmucosal troche/lozenge)
eq 0.8mg base (transmucosal troche/lozenge)
eq 1.2mg base (transmucosal troche/lozenge)
eq 1.6mg base (transmucosal troche/lozenge)
CephalonNov 4, 1998
FENTANYL CITRATE [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.05mg base/ml (injection injectable)
eq 0.2mg base (transmucosal troche/lozenge)
eq 0.4mg base (transmucosal troche/lozenge)
eq 0.6mg base (transmucosal troche/lozenge)
eq 0.8mg base (transmucosal troche/lozenge)
eq 1.2mg base (transmucosal troche/lozenge)
eq 1.6mg base (transmucosal troche/lozenge)
HospiraJan 12, 1985
MallinckrodtOct 30, 2009
Par PharmOct 30, 2009
MallinckrodtOct 30, 2009
Par PharmOct 30, 2009
FENTANYL CITRATE PRESERVATIVE FREE [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.05mg base/ml (injection injectable)
HospiraSep 24, 1991
West-ward Pharms IntJul 11, 1984
West-ward Pharms IntJul 11, 1984
FENTORA [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.1mg base (buccal, sublingual tablet)
eq 0.2mg base (buccal, sublingual tablet)
eq 0.4mg base (buccal, sublingual tablet)
eq 0.6mg base (buccal, sublingual tablet)
eq 0.8mg base (buccal, sublingual tablet)
CephalonSep 25, 2006
- Management of breakthrough pain in patients with cancer by buccal or sublingual administration of fentanyl.
- Management of breakthrough pain in patients with cancer.
LAZANDA [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.1mg base (nasal spray, metered)
eq 0.3mg base (nasal spray, metered)
eq 0.4mg base (nasal spray, metered)
Depomed IncJun 30, 2011
- Management of breakthrough pain in cancer patients 18 years of age and older who are receiving and tolerant to opioid therapy for their underlying persistent cancer pain.
- Management of breakthrough pain in patients with cancer.
SUBLIMAZE PRESERVATIVE FREE [Fentanyl CitrateC22H28N2OC6H8O7]
RX
- eq 0.05mg base/ml (injection injectable)
AkornApproved Prior To Jan 1, 1982
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.